Lipid Lowering therapies
People living with CKD are more likely to develop heart disease or strokes. The lower their eGFR, the higher this risk.
Offer lipid lowering therapy for primary prevention of CVD.
- Offer Atorvastatin 20 mg for the primary prevention of cardiovascular disease in all patients with CKD, irrespective of their serum lipid levels.
- Increase the dose if there is <40% reduction in non-HDL cholesterol and eGFR is > 30 ml/min/1.73m², particularly for secondary prevention of cardiovascular disease.
- Optimise lipid lowering therapies e.g. statin dose adjustment, addition of ezetimibe or other lipid lowering therapies according to national guidelines and local formularies.